Business
WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION
WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION Canada...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN\n \n THE UNITED STATES\n \n /\n \n \n \n \n \n SUNNYVALE, Calif.\n \n \n ,\n \n \n June 3, 2024\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a brokered private placement offering (the \"\n \n Offering\n \n \") of up to 30,000,000 units (\"\n \n Units\n \n \") of Willow at an issue price of\n \n C$0.10\n \n per Unit (the \"\n \n Offering Price\n \n \") to raise aggregate gross proceeds of up to\n \n C$3.0 million\n \n . Independent Trading Group (ITG) Inc. (the \"\n \n Agent\n \n \") has agreed to act as lead agent and sole bookrunner on a \"best efforts\" basis in connection with the Offering.\n \n \n \n \n \n \n \n \n \n Each Unit issued under the Offering shall consist of one (1) common share in the capital of the Company (each, a \"\n \n Common Share\n \n \") and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a \"\n \n Warrant\n \n \"). Each Warrant will entitle the holder thereof to acquire one (1) Common Share at an exercise price of\n \n $0.13\n \n per Common Share for a period of 36 months from the closing of the Offering (the \"\n \n Closing\n \n \"), subject to accelerated expiry in the event the volume-weighted average closing price of the Common Shares on the Toronto Stock Exchange (the \"\n \n TSX\n \n \") is equal to or exceeds\n \n $0.17\n \n for ten (10) consecutive trading days.\n \n \n Willow intends to use the net proceeds from the Offering to support the Company's enzyme engineering of existing pipeline of products, including the funding of products relating to the Company's recently announced strategic part...